1. Articles in category: Diagnosis and Detection

    1-24 of 52 1 2 3 »
    1. An Evidence-based Recommendation for a Standardized Approach to Detecting Metastatic Neuroblastoma in Staging Bone Marrow Biopsies.

      An Evidence-based Recommendation for a Standardized Approach to Detecting Metastatic Neuroblastoma in Staging Bone Marrow Biopsies.

      Pediatr Dev Pathol. 2017 Jan-Feb;20(1):38-43

      Authors: Parsons LN, Gheorghe G, Yan K, Simpson P, Jarzembowski JA

      Abstract Neuroblastoma is a common malignant tumor of childhood. Accurate bone marrow (BM) evaluation for metastatic tumor is essential; however, no standardized pathologic workup exists for staging BMs.

      Read Full Article
      Mentions: Staging Bone Marrow
    2. New assay shows promise to advance personalized therapy for cancer patients

      New assay shows promise to advance personalized therapy for cancer patients

      ( Elsevier Health Sciences ) The National Cancer Institute's NCI-MATCH (Molecular Analysis for Therapy Choice) is a large, ongoing clinical trial that matches tumors to therapies based on the tumor's genetic characteristics. A report in The Journal of Molecular Diagnostics confirms that the assay tailored for this trial is highly sensitive for detecting genetic mutations from a variety of tumor tissue and, for the first time, has been reproduced with accuracy by multiple clinical laboratories, laying the groundwork for future clinical utility.

      Read Full Article
      Mentions: Diagnostics
    3. Neuroblastoma: A spectrum of cells isolated from bone marrow of patients.

      "Flow cytometry can detect neuroblastoma cells as low as 0.001% within the heparinized samples and used to characterize the cultured cells. Cell culture showed a spectrum of neuronal morphology. Neurospheres express lower levels of GD2, TrkB, and CD56 compared to adherent neuroblastoma (consistent results were obtained using flow cytometry, immunofluoresence, immunohistochemistry, and mRNA expression analysis). Tumorigenicity was confirmed using mice injected subcutaneously with patient neurospheres tumors were present at the injection site and metastasized. Bone marrow aspirates of patients with neuroblastoma can be analyzed for the presence of neuroblastoma initiating cells which can be further characterized. This may play ...

      Read Full Article
      Mentions: Bone Marrow
    4. Patterns of Diagnosis and Misdiagnosis in Pediatric Cancer and Relationship to Survival.

      "The median time from symptom onset to diagnosis was shortest for leukemia (18.5 d) and longest for bone tumors (86.5 d). Tumor type was the only factor associated with time to diagnosis. In 52% of cases an incorrect nononcological diagnosis was initially made. Soft tissue sarcomas and brain tumors were misdiagnosed most often. Neither prolonged time to diagnosis nor initial misdiagnosis was associated with reduced survival. Tumor type and presence of metastatic disease at diagnosis were significantly associated with survival."

      Read Full Article
    5. Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients.

      "The present study reports two high-risk neuroblastoma patients, whose MRD was consecutively monitored using 11 RT-qPCR markers (CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH) during their course of treatment. The two patients initially responded to the induction therapy and reached MRD-negative status. The patients' MRD subsequently became positive with no elevation of their urinary homovanillic acid, urinary vanillylmandelic acid and serum neuron-specific enolase levels at 13 or 19 weeks prior to the clinical diagnosis of tumor relapse or regrowth. The present cases highlight the possibility of consecutive MRD monitoring using 11 markers to enable an ...

      Read Full Article
      Mentions: Relapse PHOX2B
    6. Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.

      Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.

      Oncol Lett. 2015 Nov;10(5):3228-3232

      Authors: Yamamoto N, Kozaki A, Hartomo TB, Yanai T, Hasegawa D, Kawasaki K, Kosaka Y, Matsuo M, Hirase S, Mori T, Hayakawa A, Iijima K, Nishio H, Nishimura N

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    7. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.

      "We have addressed the issue of limited access to tumor biopsies for quantitative detection of protein biomarkers by optimizing a three-color fluorescence activated cell sorting (FACS) method to purify CD45-/GD2+/CD56+ neuroblastoma cells from bone marrow. We then developed a novel quantitative measurement of MYCN protein in these isolated neuroblastoma cells, providing the potential to demonstrate proof of concept for drugs that inhibit PI3K/AKT/mTOR signaling in this disease. In addition we have established quantitative detection of three biomarkers for AKT pathway activity (phosphorylated and total AKT, GSK3β and P70S6K) in surrogate platelet-rich plasma (PRP) from pediatric patients ...

      Read Full Article
      Mentions: MYCN
    8. The Sooner the Better? How Symptom Interval Correlates With Outcome in Children and Adolescents With Solid Tumors: Regression Tree Analysis of the Findings of a Prospective Study

      "Our analysis suggests that at least a subset of patients can benefit from an earlier diagnosis in terms of survival. For others, intrinsic aggressiveness may mask the potential effect of diagnostic delays. Based on these findings, early diagnosis should remain a goal for pediatric cancer patients."

      Read Full Article
    9. Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.

      Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.

      J Epidemiol. 2015 Nov 7;

      Authors: Ioka A, Inoue M, Yoneda A, Nakamura T, Hara J, Hashii Y, Sakata N, Yamato K, Tsukuma H, Kawa K

      Read Full Article
      Mentions: Diagnostics
    10. Improving Detection of Metastatic Neuroblastoma in Bone Marrow Core Biopsies: A Proposed Immunohistochemical Approach.

      Improving Detection of Metastatic Neuroblastoma in Bone Marrow Core Biopsies: A Proposed Immunohistochemical Approach.

      Pediatr Dev Pathol. 2015 Oct 22;

      Authors: Parsons LN, Gheorghe G, Yan K, Simpson P, Jarzembowski JA

      Abstract Bone marrow (BM) involvement is common in stage 4/M neuroblastoma patients and profoundly impacts clinical decision-making and predicts outcomes, but no standard exists for immunohistochemical evaluation of staging BMs.

      Read Full Article
      Mentions: Staging Bone Marrow
    11. A Pilot Study on the Utility of Serum Metabolomics in Neuroblastoma Patients and Xenograft Models

      Improved prediction of neuroblastoma (NB) behavior is needed to detect treatment-refractory disease and may allow further reduction in therapy for some patients. In this regard, serum metabolomic analysis has proven utility in several cancer types. We hypothesize that serum metabolomic analysis will correlate with risk-group classification for patients with NB, and sensitively detect NB in murine xenograft models.

      Read Full Article
    12. High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles.

      High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles.

      Nanomedicine (Lond). 2015 Sep 30;

      Authors: Baiu DC, Artz NS, McElreath MR, Menapace BD, Hernando D, Reeder SB, Grüttner C, Otto M

      Read Full Article
      Mentions: Nanoparticles
    13. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

      123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

      Cochrane Database Syst Rev. 2015 Sep 29;9:CD009263

      Authors: Bleeker G, Tytgat GA, Adam JA, Caron HN, Kremer LC, Hooft L, van Dalen EC

      Abstract BACKGROUND: Neuroblastoma is an embryonic tumour of childhood that originates in the neural crest.

      Read Full Article
      Mentions: Imaging MIBG
    14. Early Detection and Treatment of Neuroblastic Tumor with Opsoclonus-Myoclonus Syndrome Improve Neurological Outcome: A Review of Five Cases at a Single Institution in Japan.

      Early Detection and Treatment of Neuroblastic Tumor with Opsoclonus-Myoclonus Syndrome Improve Neurological Outcome: A Review of Five Cases at a Single Institution in Japan.

      Eur J Pediatr Surg. 2015 Sep 26;

      Authors: Takama Y, Yoneda A, Nakamura T, Nakaoka T, Higashio A, Santo K, Kuki I, Kawawaki H, Tomiwa K, Hara J

      Read Full Article
    15. Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors.

      Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors.

      J Pediatr Surg. 2015 Aug 28;

      Authors: Kurihara S, Ueda Y, Onitake Y, Sueda T, Ohta E, Morihara N, Hirano S, Irisuna F, Hiyama E

      Abstract PURPOSE: Our aims are to determine circulating free DNA (cfDNA) in childhood solid tumor patients who underwent surgical intervention and to analyze any relationships with clinical parameters.

      Read Full Article
    16. Enriched Bone Marrow Derived Disseminated Neuroblastoma Cells Can Be a Reliable Source for Gene Expression Studies-A Validation Study.

      "Using neuroblastoma as a model, we show that tumor cell enrichment by magnetic bead separation has virtually no effect on gene expression in DTCs. However, transport time and temperature can influence the expression profile remarkably. Thus, the expression profile of routinely collected BM samples can be analyzed without concern as long as the transport conditions are monitored."

      Read Full Article
      Mentions: Bone Marrow
    17. Selected Diagnostically Challenging Pediatric Soft Tissue Tumors.

      Selected Diagnostically Challenging Pediatric Soft Tissue Tumors.

      Surg Pathol Clin. 2015 Sep;8(3):399-418

      Authors: Al-Ibraheemi A, Kozakewich H, Perez-Atayde AR

      Abstract Many benign and malignant soft tissue tumors in children are challenging and their diagnosis requires knowledge of their vast diversity, histopathological complexity, and immunohistochemical, cytogenetic, and molecular characteristics. The importance of clinical and imaging features cannot be overstated.

      Read Full Article
    18. Researchers discover cancer markers may be visible early during human development

      BLACKSBURG, Va. – Researchers at the Virginia Bioinformatics Institute have uncovered a link between the genomes of cells originating in the neural crest and development of tumors — a discovery that could lead to new ways to diagnose and treat cancer. The new finding, recently published in Oncotarget, resolves why some cancer types share genomic and clinical features.

      Read Full Article
    19. Pinpointing Mutations in a Relapsed Cancer May Lead to Better Treatments

      Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children.

      “Our greater understanding of mutations on a crucial biological pathway offers prospects of acting on these pathways for direct benefit to children with this aggressive form of neuroblastoma,” said senior author John M. Maris, MD, a pediatric oncologistat The Children’s Hospital of Philadelphia.

      Read Full Article
    20. Programmed Bacteria Can Detect Tumors

      Programmed Bacteria Can Detect Tumors

      Sangeeta Bhatia of MIT is a liver expert and senior author of one of the papers. Her lab had been trying to figure out how to get nanoparticles to the liver that would send a signal detectable in urine if they encountered a tumor. Cancers that start in the colon or pancreas can metastasize to the liver, which can be deadly.

      Read Full Article
      Mentions: Nanoparticles
    1-24 of 52 1 2 3 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles